Vujaklija Brajkovic Ana, Markota Andrej, Bielen Luka, Vujević Andro, Rora Mia, Radonic Radovan
Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb 10000, Croatia.
School of Medicine, University of Zagreb, Zagreb 10000, Croatia.
World J Crit Care Med. 2024 Dec 9;13(4):96755. doi: 10.5492/wjccm.v13.i4.96755.
The initial trials on angiotensin II (AT II) administration indicated a high incidence of thrombocytopenia and thrombosis, as well as a positive correlation between hyperreninemia and response to the medication.
We describe a case of a patient presenting with catecholamine resistant septic shock, thrombocytopenia, deep vein thrombosis, and normal renin concentration who responded immediately to AT II treatment. We observed no worsening of thrombocytopenia and no progression of thrombosis or additional thromboses during treatment.
Our case underscores the need for individualized assessment of patients for potential therapy with AT II.
最初关于给予血管紧张素II(AT II)的试验表明,血小板减少症和血栓形成的发生率很高,以及高肾素血症与药物反应之间呈正相关。
我们描述了一例儿茶酚胺抵抗性感染性休克、血小板减少症、深静脉血栓形成且肾素浓度正常的患者,该患者对AT II治疗立即产生反应。在治疗期间,我们观察到血小板减少症没有恶化,血栓形成没有进展或出现额外的血栓。
我们的病例强调了对患者进行个体化评估以确定是否适合使用AT II进行潜在治疗的必要性。